

FACTSET - ISM Model Portfolios

Refresh Report  Refresh via Email Reply 

Price Performance: PRICE GAINERS(US PRE MARKET) Updated: 08:10 AM (EST/EDT), 06 Jan '23

[Remove](#)

Company	Position	PrevClose (LOCAL)	Off-Hr Chg (LOCAL)	Off-Hr %Chg	Off-Hr cVol	Tick
IRM-USA <i>Iron Mountain, Inc.</i>	L	48.95	2.13	4.35	67	RT
COST-USA <i>Costco Wholesale Corporation</i>	L	450.19	9.69	2.15	8,975	RT
TAP-USA <i>Molson Coors Beverage Company Class B</i>	L	49.58	0.64	1.29	542	RT
CC-USA <i>Chemours Co.</i>	L	30.70	0.36	1.17	2	RT
JEF-USA <i>Jefferies Financial Group Inc.</i>	L	37.07	0.43	1.16	521	RT
NTR-USA <i>Nutrien Ltd.</i>	L	74.52	0.73	0.98	95	RT
CMI-USA <i>Cummins Inc.</i>	L	236.72	2.05	0.87	25	RT
CMG-USA <i>Chipotle Mexican Grill, Inc.</i>	L	1,364.16	7.83	0.57	12	RT
VZ-USA <i>Verizon Communications Inc.</i>	L	41.70	0.20	0.48	16,059	RT
PHM-USA <i>PulteGroup, Inc.</i>	L	47.67	0.21	0.44	10	RT

Notes: Tick type descriptions

RT = real time DL = delayed SNAP = real time snapshot EOD = end of day NONE = no access or invalid ticker.

Price Performance: PRICE LOSERS(US PRE MARKET) Updated: 08:10 AM (EST/EDT), 06 Jan '23

[Remove](#)

Company	Position	PrevClose (LOCAL)	Off-Hr Chg (LOCAL)	Off-Hr %Chg	Off-Hr cVol	Tick
TSLA-USA <i>Tesla Inc</i>	L	110.34	-7.13	-6.46	5,314,484	RT
NUE-USA <i>Nucor Corporation</i>	L	137.05	-1.76	-1.28	82	RT
GSK-USA <i>GSK plc Sponsored ADR</i>	L	34.48	-0.43	-1.26	12,477	RT
META-USA <i>Meta Platforms Inc. Class A</i>	L	126.94	-0.86	-0.68	134,032	RT
LLY-USA <i>Eli Lilly and Company</i>	L	358.92	-2.43	-0.68	1,437	RT
UNH-USA <i>UnitedHealth Group Incorporated</i>	L	489.96	-2.75	-0.56	2,566	RT
BAC-USA <i>Bank of America Corp</i>	L	34.07	-0.16	-0.47	69,466	RT
AMZN-USA <i>Amazon.com, Inc.</i>	L	83.12	-0.38	-0.45	319,462	RT
PANW-USA <i>Palo Alto Networks, Inc.</i>	L	135.11	-0.61	-0.45	1,191	RT
SBUX-USA <i>Starbucks Corporation</i>	L	104.43	-0.34	-0.33	2,352	RT

Notes: Tick type descriptions

RT = real time DL = delayed SNAP = real time snapshot EOD = end of day NONE = no access or invalid ticker.

Event Calendar(5D): Conferences And Webcasts(Earnings Calls) Updated: 08:10 AM (EST/EDT), 06 Jan '23





[Remove](#)

Company	Date	Time (EST)	Event Type	Calendar	Company Book
AYI-US <i>Acuity Brands, Inc.</i>	01/09/2023	8:00 AM	Q1 2023 Earnings Call		

Event Calendar(5D): Financial Releases(Confirmed) Updated: 08:10 AM (EST/EDT), 06 Jan '23

[Remove](#)

Company	Date	Time (EST)	Event Type	Calendar	Company Book
---------	------	------------	------------	----------	--------------

CNXC-US <i>Concentrix Corp.</i>	01/09/2023	After Market	Q4 2022 Earnings Release		
JEF-US <i>Jefferies Financial Group, Inc.</i>	01/09/2023	After Market	Q4 2022 Earnings Release		
AYI-US <i>Acuity Brands, Inc.</i>	01/09/2023	6:00 AM	Q1 2023 Earnings Release		

Today's Stock Dividends Updated: 08:10 AM (EST/EDT), 06 Jan '23

[Remove](#)

Ticker	Dividend Amount	Ex-Date	Record Date	Pay Date	Type
MA-USA <i>Mastercard Incorporated Class A</i>	0.57	06-Jan-'23	09-Jan-'23	09-Feb-'23	U.S. Currency

StreetAccount Portfolio News Updated: 08:10 AM (EST/EDT), 06 Jan '23

[Remove](#)

08:01 AM (EST/EDT)
06 Jan '23

ABBV-USA, ABBV-US, IMNM-US

AbbVie and Immunome (IMNM) announce strategic collaboration to discover multiple novel oncology targets (\$163.49, 0.00)

- AbbVie and Immunome, Inc. (IMNM) announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.
- Under the terms of the agreement, Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumors.
 - Immunome will receive an **upfront payment of \$30M and will be eligible to receive additional platform access payments in the aggregate amount of up to \$70M** based on AbbVie's election for Immunome to continue research using its Discovery Engine.
 - Immunome is also eligible to receive **development and first commercial sale milestones of up to \$120M per target** with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales.

07:35 AM (EST/EDT)
06 Jan '23

TAP-USA, STZ-US, TAP-US

Cowen upgrades TAP; downgrades STZ

- Upgrade:**
 - Molson Coors Beverage (**TAP** \$49.58) upgraded to outperform from market perform; target increased to \$60 from \$55, 21% upside (FactSet average target ~\$54; range \$45-69)
- Downgrade:**
 - Constellation Brands (**STZ** \$208.68) downgraded to market perform from outperform; target cut to \$200 from \$275, 4% downside (FactSet average target ~\$256; range \$200-300)
- Analyst is Vivien Azer

06:47 AM (EST/EDT)
06 Jan '23

PFE-USA, PFE-US

Pfizer announces FDA accepts for priority review its sBLA for 20-valent pneumococcal conjugate vaccine in infants and children (\$49.66, 0.00)

- Pfizer announced that the FDA accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 *Streptococcus pneumoniae* (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of otitis media caused by seven of the 20 *Streptococcus pneumoniae* serotypes contained in the vaccine.
- Priority Review designation by the FDA reduces the standard sBLA review period by four months. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA on the 20vPnC vaccine application is anticipated in April 2023

05:15 AM (EST/EDT)
06 Jan '23

META-USA, META-US

UK's CMA makes final order in connection with Giphy deal (\$126.94, 0.00)

- Company has to divest the Giphy business to a purchaser put forward by Meta for approval by the CMA

12:23 AM (EST/EDT)
06 Jan '23

TM-USA, 7201-JP, 7203-JP, 7211-JP, 7267-JP

Japan new car sales drop to 45-year low:

- Kyodo** cited industry group data released Thursday afternoon that showed **Japan new car sales fell 5.6% in 2022 to 4.2M, the lowest in 45 years**, due to semiconductor shortages and pandemic-induced supply chain disruptions. This was also the fourth straight annual decline. **Toyota** (7203.JP) saw a 12.4% decrease, **Nissan** (7201.JP) sales fell 0.8%, and **Honda** (7267.JP) slid 1.9%. Other automakers logged growth, led by a 42.4% rise at **Mitsubishi** (7211.JP) on the back of its Outlander PHEV and electric mini vehicles. Separately, **mini-car sales fell 0.9%** as Daihatsu sales increased 1.2% while Suzuki fell 1.5%. **Weakness extended overseas** indicated by a sharp 17.9% drop in US sales with all major manufacturers contributing negatively and **Toyota losing its top spot in market share to GM**. Press have widely discussed this as primarily a supply-side issue, underscored by extended delivery times.
- For the latest updates on this story and all top news, please visit the Asia Today's Top News page.

Recent Enhancements:

1. You may now customize which currency prices are displayed in within the Price Performance and Estimates Monitor sections.
2. Signals on your portfolio are now available and will reflect any updates within the past 24 hours. Signals are specific indicators that may signal risk or be of interest for further analysis.

Note: To take advantage of these new features, please go to FactSet/Market Intelligence

The delivery settings and content of this report can be edited in Factset [Web](#) or [Workstation](#). Click here to [unsubscribe](#).

This email and/or attachment are confidential and intended solely for the use of the individual to whom they are addressed. Disclosing, copying or distributing the contents of this email is prohibited. FactSet Research Systems Inc. does not accept liability for the content of this email, or for the consequences of any actions or inactions taken on the basis of the information provided. The content of this email is not investment advice and any opinions or assertion contained in this email do not represent the opinions or beliefs of FactSet Research Systems Inc. or its affiliates or any of their respective employees. If you are not entitled to receive this e-mail or have questions regarding news and research services in FactSet, please contact FactSet at support@factset.com